{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:02:48Z","timestamp":1770818568597,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-01371-y","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:23:58Z","timestamp":1768307038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarised 13C-MRI and mass spectrometry imaging"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1373-6944","authenticated-orcid":false,"given":"Ines","family":"Horvat-Menih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Casey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-3134","authenticated-orcid":false,"given":"James","family":"Denholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Hulme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-6298","authenticated-orcid":false,"given":"John","family":"Gallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alixander S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Kaggie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9287-9563","authenticated-orcid":false,"given":"Andrew B.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9771-4290","authenticated-orcid":false,"given":"Andrew N.","family":"Priest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao A. G.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cissy","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Whitworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8511-0588","authenticated-orcid":false,"given":"Simon T.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-8488","authenticated-orcid":false,"given":"Richard J. A.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubha","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Honan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Y.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tevita","family":"Aho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant D.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3752-0179","authenticated-orcid":false,"given":"Mary A.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdia A.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"1371_CR1","doi-asserted-by":"crossref","unstructured":"Lara, Jr., P. N. & Jonasch, E. Kidney Cancer: Principles and Practice. Springer. (2015).","DOI":"10.1007\/978-3-319-17903-2"},{"key":"1371_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fonc.2012.00085","volume":"2","author":"M Yang","year":"2012","unstructured":"Yang, M., Soga, T., Pollard, P. J. & Adam, J. The emerging role of fumarate as an oncometabolite. Front. Oncol. 2, 85 (2012).","journal-title":"Front. Oncol."},{"key":"1371_CR3","unstructured":"Bex, A. et al. EAU Guidelines: Renal Cell Carcinoma. Uroweb https:\/\/uroweb.org\/guideline\/renal-cell-carcinoma\/ (Accessed online 2023)."},{"key":"1371_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 706\u2013720 (2019).","journal-title":"Ann. Oncol."},{"key":"1371_CR5","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.euo.2019.11.002","volume":"3","author":"C Forde","year":"2020","unstructured":"Forde, C. et al. Hereditary Leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals. Eur. Urol. Oncol. 3, 764\u2013772 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"1371_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.eururo.2022.01.040","volume":"81","author":"E Roussel","year":"2022","unstructured":"Roussel, E. et al. Novel imaging methods for renal mass characterization: a collaborative review. Eur. Urol. 81, 476\u2013488 (2022).","journal-title":"Eur. Urol."},{"key":"1371_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0140-6736(22)01059-5","volume":"400","author":"GD Stewart","year":"2022","unstructured":"Stewart, G. D. et al. The multispeciality approach to the management of localised kidney cancer. Lancet 400, 523\u2013534 (2022).","journal-title":"Lancet"},{"key":"1371_CR8","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.juro.2015.11.029","volume":"195","author":"HD Patel","year":"2016","unstructured":"Patel, H. D. et al. Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature. J. Urol. 195, 1340\u20131347 (2016).","journal-title":"J. Urol."},{"key":"1371_CR9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1464-410X.2012.10944.x","volume":"110","author":"CR Harris","year":"2012","unstructured":"Harris, C. R., Whitson, J. M. & Meng, M. V. Under-grading of <4 cm renal masses on renal biopsy. BJU Int. 110, 794\u2013797 (2012).","journal-title":"BJU Int."},{"key":"1371_CR10","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","volume":"19","author":"WM Linehan","year":"2013","unstructured":"Linehan, W. M. & Rouault, T. A. Molecular pathways: Fumarate Hydratase -deficient kidney cancer\u2014targeting the Warburg effect in cancer. Clin. Cancer Res. 19, 3345\u20133352 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1371_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906014","volume":"12","author":"AK Lindner","year":"2022","unstructured":"Lindner, A. K. et al. Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma. Front. Oncol. 12, 906014 (2022).","journal-title":"Front. Oncol."},{"key":"1371_CR12","doi-asserted-by":"publisher","first-page":"686556","DOI":"10.3389\/fonc.2021.686556","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang, C., Li, L., Zhang, Y. & Zeng, C. Hereditary leiomyomatosis and renal cell cancer: recent insights into mechanisms and systemic treatment. Front. Oncol. 11, 686556 (2021).","journal-title":"Front. Oncol."},{"key":"1371_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/CCO.0000000000000518","volume":"31","author":"L Lindenberg","year":"2019","unstructured":"Lindenberg, L., Mena, E., Choyke, P. L. & Bouchelouche, K. PET imaging in renal cancer. Curr. Opin. Oncol. 31, 216\u2013221 (2019).","journal-title":"Curr. Opin. Oncol."},{"key":"1371_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/1078-0432.CCR-19-1729","volume":"26","author":"RT Casey","year":"2020","unstructured":"Casey, R. T. et al. Fumarate metabolic signature for the detection of Reed syndrome in humans. Clin. Cancer Res 26, 391\u2013396 (2020).","journal-title":"Clin. Cancer Res"},{"key":"1371_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jceh.2015.10.006","volume":"5","author":"JM Tognarelli","year":"2015","unstructured":"Tognarelli, J. M. et al. Magnetic resonance spectroscopy: principles and techniques: lessons for clinicians. J. Clin. Exp. Hepatol. 5, 320\u2013328 (2015).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"1371_CR16","doi-asserted-by":"crossref","unstructured":"McRobbie, D. W., Moore, E. A. & Graves, M. J. MRI from Picture to Proton. (Cambridge Univ. Press, Cambridge, 2017).","DOI":"10.1017\/9781107706958"},{"key":"1371_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41551-020-0535-8","volume":"4","author":"PCM van Zijl","year":"2020","unstructured":"van Zijl, P. C. M. & Brindle, K. M. Spectroscopic measurements of metabolic fluxes. Nat. Biomed. Eng. 4, 254\u2013256 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"1371_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/metabo11040219","volume":"11","author":"M Vaeggemose","year":"2021","unstructured":"Vaeggemose, M., Schulte, F. R. & Laustsen, C. Comprehensive literature review of hyperpolarized carbon-13 MRI: the road to clinical application. Metabolites 11, 219 (2021).","journal-title":"Metabolites"},{"key":"1371_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2018.09.006","volume":"21","author":"J Kurhanewicz","year":"2018","unstructured":"Kurhanewicz, J. et al. Hyperpolarized 13C MRI: path to clinical translation in oncology. Neoplasia 21, 1\u201316 (2018).","journal-title":"Neoplasia"},{"key":"1371_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/cancers14020335","volume":"14","author":"S Ursprung","year":"2022","unstructured":"Ursprung, S. et al. Hyperpolarized 13C-pyruvate metabolism as a surrogate for tumor grade and poor outcome in renal cell carcinoma\u2014a proof of principle study. Cancers 14, 335 (2022).","journal-title":"Cancers"},{"key":"1371_CR21","doi-asserted-by":"publisher","unstructured":"Tang, S. et al. Metabolic imaging with hyperpolarized 13 C pyruvate magnetic resonance imaging in patients with renal tumors\u2014Initial experience. Cancer https:\/\/doi.org\/10.1002\/cncr.33554 (2021).","DOI":"10.1002\/cncr.33554"},{"key":"1371_CR22","first-page":"20190003","volume":"5","author":"M Tran","year":"2019","unstructured":"Tran, M. et al. First-in-human in vivo non-invasive assessment of intra-tumoral metabolic heterogeneity in renal cell carcinoma. BJR Case Rep. 5, 20190003 (2019).","journal-title":"BJR Case Rep."},{"key":"1371_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41590-020-0745-y","volume":"21","author":"MJ Schuijs","year":"2020","unstructured":"Schuijs, M. J. et al. ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung. Nat. Immunol. 21, 998\u20131009 (2020).","journal-title":"Nat. Immunol."},{"key":"1371_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41588-020-00753-3","volume":"53","author":"CRUK Rosetta Grand Challenge Consor","year":"2021","unstructured":"CRUK Rosetta Grand Challenge Consortium et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nat. Genet. 53, 16\u201326 (2021).","journal-title":"Nat. Genet."},{"key":"1371_CR25","doi-asserted-by":"crossref","unstructured":"Sushentsev, N. et al. Metabolic imaging across scales reveals distinct prostate cancer phenotypes. Nat. Commun. 15, 5980 (2024).","DOI":"10.1038\/s41467-024-50362-5"},{"key":"1371_CR26","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1073\/pnas.1913841117","volume":"117","author":"FA Gallagher","year":"2020","unstructured":"Gallagher, F. A. et al. Imaging breast cancer using hyperpolarized carbon-13 MRI. Proc. Natl. Acad. Sci. USA 117, 2092\u20132098 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1371_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mrm.23212","volume":"68","author":"F Wiesinger","year":"2012","unstructured":"Wiesinger, F. et al. IDEAL spiral CSI for dynamic metabolic MR imaging of hyperpolarized [1-13 C]pyruvate. Magn. Reson. Med. 68, 8\u201316 (2012).","journal-title":"Magn. Reson. Med."},{"key":"1371_CR28","unstructured":"Tofts, P. S. T1-weighted DCE imaging concepts: modelling, acquisition and analysis. Siemens MAGNETOM Flash. 3, 30\u201339 (2010)."},{"key":"1371_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/mrm.1910360209","volume":"36","author":"T Fritz-Hansen","year":"1996","unstructured":"Fritz-Hansen, T. et al. Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging. Magn. Reson. Med. 36, 225\u2013231 (1996).","journal-title":"Magn. Reson. Med."},{"key":"1371_CR30","first-page":"167","volume":"16","author":"HJ Weinmann","year":"1984","unstructured":"Weinmann, H. J., Laniado, M. & M\u00fctzel, W. Pharmacokinetics of GdDTPA\/dimeglumine after intravenous injection into healthy volunteers. Physiol. Chem. Phys. Med. NMR 16, 167\u2013172 (1984).","journal-title":"Physiol. Chem. Phys. Med. NMR"},{"key":"1371_CR31","doi-asserted-by":"publisher","first-page":"11080","DOI":"10.1021\/acs.analchem.0c00826","volume":"92","author":"A Dannhorn","year":"2020","unstructured":"Dannhorn, A. et al. Universal sample preparation unlocking multimodal molecular tissue imaging. Anal. Chem. 92, 11080\u201311088 (2020).","journal-title":"Anal. Chem."},{"key":"1371_CR32","doi-asserted-by":"publisher","first-page":"59492","DOI":"10.18632\/oncotarget.17752","volume":"8","author":"A Surov","year":"2017","unstructured":"Surov, A., Meyer, H. J. & Wienke, A. Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis. Oncotarget 8, 59492\u201359499 (2017).","journal-title":"Oncotarget"},{"key":"1371_CR33","doi-asserted-by":"publisher","first-page":"22378","DOI":"10.1073\/pnas.2003537117","volume":"117","author":"Y Rao","year":"2020","unstructured":"Rao, Y. et al. Hyperpolarized [1-13C]pyruvate-to-[1-13C]lactate conversion is rate-limited by monocarboxylate transporter-1 in the plasma membrane. Proc. Natl. Acad. Sci. USA 117, 22378\u201322389 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1371_CR34","doi-asserted-by":"publisher","unstructured":"Casey, R. T. et al. Translating in vivo metabolomic analysis of succinate dehydrogenase\u2013deficient tumors into clinical utility. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.17.00191 (2018).","DOI":"10.1200\/PO.17.00191"},{"key":"1371_CR35","unstructured":"ClinVar. VCV000296865.18 - ClinVar - NCBI. National Center for Biotechnology Information. ClinVar; [VCV000296865.18]. https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/296865\/ (Accessed online 2024)."},{"key":"1371_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajhg.2017.01.004","volume":"100","author":"Q Li","year":"2017","unstructured":"Li, Q. & Wang, K. InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP Guidelines. Am. J. Hum. Genet. 100, 267\u2013280 (2017).","journal-title":"Am. J. Hum. Genet."},{"key":"1371_CR37","unstructured":"KDR p.Q472H | OncoKBTM. https:\/\/www.oncokb.org\/gene\/KDR\/p.Q472H (Accessed online 2023)."},{"key":"1371_CR38","first-page":"PO.17.00011","volume":"2017","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017, PO.17.00011 (2017).","journal-title":"JCO Precis. Oncol."},{"key":"1371_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00424-013-1369-y","volume":"466","author":"AM Pajor","year":"2014","unstructured":"Pajor, A. M. Sodium-coupled dicarboxylate and citrate transporters from the SLC13 family. Pflug. Arch. 466, 119\u2013130 (2014).","journal-title":"Pflug. Arch."},{"key":"1371_CR40","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s43018-022-00356-3","volume":"3","author":"T Chu","year":"2022","unstructured":"Chu, T., Wang, Z., Pe\u2019er, D. & Danko, C. G. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology. Nat. Cancer 3, 505\u2013517 (2022).","journal-title":"Nat. Cancer"},{"key":"1371_CR41","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-20-3788","volume":"27","author":"G Sun","year":"2021","unstructured":"Sun, G. et al. Integrated molecular characterization of fumarate hydratase\u2013deficient renal cell carcinoma. Clin. Cancer Res. 27, 1734\u20131743 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1371_CR42","doi-asserted-by":"publisher","first-page":"7146","DOI":"10.3390\/ijms21197146","volume":"21","author":"J Courcier","year":"2020","unstructured":"Courcier, J. et al. Carbonic anhydrase IX in renal cell carcinoma, implications for disease management. Int. J. Mol. Sci. 21, 7146 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1371_CR43","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/2159-8290.CD-22-0874","volume":"13","author":"BR Wilde","year":"2023","unstructured":"Wilde, B. R. et al. FH variant pathogenicity promotes purine salvage pathway dependence in kidney cancer. Cancer Discov. 13, 2072\u20132089 (2023).","journal-title":"Cancer Discov."},{"key":"1371_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41589-018-0217-y","volume":"15","author":"RA Kulkarni","year":"2019","unstructured":"Kulkarni, R. A. et al. A chemoproteomic portrait of the oncometabolite fumarate. Nat. Chem. Biol. 15, 391\u2013400 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"1371_CR45","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00066-014-0611-7","volume":"190","author":"I Apostolova","year":"2014","unstructured":"Apostolova, I. et al. Combined measurement of tumor perfusion and glucose metabolism for improved tumor characterization in advanced cervical carcinoma: A PET\/CT pilot study using [15O]water and [18F]fluorodeoxyglucose. Strahlenther. Onkol. 190, 575\u2013581 (2014).","journal-title":"Strahlenther. Onkol."},{"key":"1371_CR46","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1158\/1078-0432.CCR-09-0414","volume":"15","author":"G Komar","year":"2009","unstructured":"Komar, G. et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin. Cancer Res. 15, 5511\u20135517 (2009).","journal-title":"Clin. Cancer Res."},{"key":"1371_CR47","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1158\/1078-0432.CCR-10-0026","volume":"16","author":"JM Specht","year":"2010","unstructured":"Specht, J. M. et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin. Cancer Res. 16, 2803\u20132810 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1371_CR48","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/genes10040264","volume":"10","author":"A Lameirinhas","year":"2019","unstructured":"Lameirinhas, A., Miranda-Gon\u00e7alves, V., Henrique, R. & Jer\u00f3nimo, C. The complex interplay between metabolic reprogramming and epigenetic alterations in renal cell carcinoma. Genes 10, 264 (2019).","journal-title":"Genes"},{"key":"1371_CR49","doi-asserted-by":"publisher","first-page":"1218297","DOI":"10.1155\/2018\/1218297","volume":"2018","author":"F Erra D\u00edaz","year":"2018","unstructured":"Erra D\u00edaz, F., Dantas, E. & Geffner, J. Unravelling the interplay between extracellular acidosis and immune cells. Mediators Inflamm. 2018, 1218297 (2018).","journal-title":"Mediators Inflamm."},{"key":"1371_CR50","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cmet.2023.04.017","volume":"35","author":"J Cheng","year":"2023","unstructured":"Cheng, J. et al. Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment. Cell Metab. 35, 961\u2013978.e10 (2023).","journal-title":"Cell Metab."},{"key":"1371_CR51","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865.e7 (2021).","journal-title":"Cancer Cell"},{"key":"1371_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36769-6","volume":"14","author":"B Calsina","year":"2023","unstructured":"Calsina, B. et al. Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma. Nat. Commun. 14, 1122 (2023).","journal-title":"Nat. Commun."},{"key":"1371_CR53","doi-asserted-by":"publisher","first-page":"735077","DOI":"10.3389\/fonc.2021.735077","volume":"11","author":"T Wang","year":"2021","unstructured":"Wang, T. et al. Complete response of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-associated renal cell carcinoma to pembrolizumab immunotherapy: a case report. Front. Oncol. 11, 735077 (2021).","journal-title":"Front. Oncol."},{"key":"1371_CR54","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.21037\/tau-21-644","volume":"10","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Stereotactic body radiotherapy-induced abscopal effect twice after pembrolizumab failure in hereditary leiomyomatosis and renal cell carcinoma: a case report with genetic and immunologic analysis. Transl. Androl. Urol. 10, 4304\u20134312 (2021).","journal-title":"Transl. Androl. Urol."},{"key":"1371_CR55","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","volume":"21","author":"K DePeaux","year":"2021","unstructured":"DePeaux, K. & Delgoffe, G. M. Metabolic barriers to cancer immunotherapy. Nat. Rev. Immunol. 21, 785\u2013797 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1371_CR56","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/cancers17040569","volume":"17","author":"I Horvat-Menih","year":"2025","unstructured":"Horvat-Menih, I. et al. K-means clustering of hyperpolarised 13C-MRI identifies intratumoral perfusion\/metabolism mismatch in renal cell carcinoma as the best predictor of the highest grade. Cancers 17, 569 (2025).","journal-title":"Cancers"},{"key":"1371_CR57","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11307-023-01888-5","volume":"26","author":"MM Chaumeil","year":"2024","unstructured":"Chaumeil, M. M. et al. New horizons in hyperpolarized 13C MRI. Mol. Imaging Biol. 26, 222\u2013232 (2024).","journal-title":"Mol. Imaging Biol."},{"key":"1371_CR58","doi-asserted-by":"publisher","first-page":"e083980","DOI":"10.1136\/bmjopen-2024-083980","volume":"14","author":"I Horvat-Menih","year":"2024","unstructured":"Horvat-Menih, I. et al. Multiarm, non-randomised, single-centre feasibility study\u2014investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): protocol. BMJ Open 14, e083980 (2024).","journal-title":"BMJ Open"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01371-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01371-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01371-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:03:11Z","timestamp":1770814991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01371-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1371"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01371-y","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.D.S. has received educational grants from Pfizer, AstraZeneca and Intuitive Surgical; consultancy fees from Pfizer, MSD, EUSA Pharma and CMR Surgical; Travel expenses from MSD and Pfizer; Speaker fees from Pfizer; he is Clinical Lead (urology), National Kidney Cancer Audit and Topic Advisor for the NICE kidney cancer guideline. S.J.W. is a founder and director of Pinto Medical Consultancy. F.A.G. has research grants from GlaxoSmithKline, AstraZeneca, and NVision, research and conference support from GE Healthcare, and has consulted for AstraZeneca on behalf of the University of Cambridge.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}